We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

113 hedge funds and large institutions have $623M invested in Relmada Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

97% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $13.4M

95% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 21

33% more capital invested

Capital invested by funds: $467M → $623M (+$156M)

16% more funds holding

Funds holding: 97 → 113 (+16)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

39.73% less ownership

Funds ownership: 118.31% → 78.58% (-40%)

Holders
113
Holders Change
+16
Holders Change %
+16.49%
% of All Funds
1.78%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
29
Increased
41
Reduced
21
Closed
13
Calls
$26.4M
Puts
$13.4M
Net Calls
+$13M
Net Calls Change
+$10.4M

Top Buyers

1
CAC
Cowen and Company
New York
+$21M
2
Citadel Advisors
Citadel Advisors
Florida
+$13.3M
3
BlackRock
BlackRock
New York
+$11.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.57M
5
RI
RTW Investments
New York
+$7.31M

Top Sellers

1
APM
Avidity Partners Management
Texas
-$16.5M
2
LGM
Logos Global Management
California
-$9.01M
3
Morgan Stanley
Morgan Stanley
New York
-$6.35M
4
Millennium Management
Millennium Management
New York
-$5.67M
5
SFM
Sphera Funds Management
Israel
-$3.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
26
Perceptive Advisors
New York
$4.08M +$3.13M +151,350 New
MB
27
MPM BioImpact
Massachusetts
$3.73M +$2.85M +138,000 New
CS
28
Candriam SCA
Luxembourg
$3.66M +$2.81M +135,676 New
Walleye Capital
29
Walleye Capital
New York
$3.33M +$2.12M +102,410 +492%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$3.26M +$1.15M +55,685 +86%
SG Americas Securities
31
SG Americas Securities
New York
$2.83M -$1.03M -49,633 -32%
DTC
32
Deep Track Capital
Connecticut
$2.76M +$2.11M +102,117 New
GTC
33
Ghost Tree Capital
New York
$2.7M -$2.07M -100,000 -50%
Charles Schwab
34
Charles Schwab
California
$1.81M +$447K +21,621 +48%
N
35
Nuveen
North Carolina
$1.62M +$255K +12,333 +21%
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.51M +$84.8K +4,100 +8%
Jane Street
37
Jane Street
New York
$1.5M +$1.15M +55,743 New
Citigroup
38
Citigroup
New York
$942K +$618K +29,891 +596%
CSS
39
Cubist Systematic Strategies
Connecticut
$910K +$679K +32,822 +3,611%
AW
40
Apricus Wealth
South Carolina
$885K – – –
MHC
41
Meyer Handelman Company
New York
$878K – – –
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$843K +$59.1K +2,856 +10%
Goldman Sachs
43
Goldman Sachs
New York
$791K -$1.14M -54,997 -65%
IBT
44
International Biotechnology Trust
United Kingdom
$741K – – –
PAM
45
Pegasus Asset Management
New York
$728K – – –
Wells Fargo
46
Wells Fargo
California
$654K +$328K +15,841 +189%
UBS AM
47
UBS AM
Illinois
$651K +$499K +24,120 New
CL
48
CSS LLC
Illinois
$605K +$53.2K +2,572 +13%
IC
49
Ikarian Capital
Texas
$588K +$21.9K +1,058 +5%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$582K +$124K +5,975 +38%
1
2
3 4 5

RLMD Hedge Fund Activity: Q1 2022 in Review

113 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2022, worth a combined $623M — up 33% from $467M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new RLMD positions and 13 closed out — a net gain of 16 holders — while 41 added to existing stakes and 21 trimmed.

The largest buyer was Cowen and Company, adding an estimated $21M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $16.5M sold.

  • 113 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2022, up from 97 in Q4 2021.
  • Funds reported $623M of Relmada Therapeutics stock for Q1 2022, up 33% quarter-over-quarter.
  • 29 funds opened new Relmada Therapeutics positions in Q1 2022 and 13 closed out, a net change of +16 holders.
  • The largest Relmada Therapeutics buyer in Q1 2022 was Cowen and Company, an estimated $21M added.
  • The largest Relmada Therapeutics seller in Q1 2022 was Avidity Partners Management, an estimated $16.5M sold.

Based on aggregated 13F filings for Q1 2022.